Abstract
Abstract The time for “one size fits all” treatment is over in endometrial cancer. Endometrial cancer has a number of potential targetable molecular aberrations, including those that predict response to DNA damaging agents such as PARP inhibitors. This talk will explore the preclinical and clinical data to support DNA damaging agents, alone and in combination, in the treatment of endometrial cancer. Biomarkers for response will be critically reviewed. Citation Format: Shannon Neville Westin. DNA damaging agents in endometrial cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr IA005.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
